183 related articles for article (PubMed ID: 38349538)
1. High-volume facilities are significantly more likely to use guideline-adherent systemic immunotherapy for metastatic Merkel cell carcinoma: implications for cancer care regionalization.
Cheraghlou S; Pahalyants V; Jairath NK; Doudican NA; Carucci JA
Arch Dermatol Res; 2024 Feb; 316(3):86. PubMed ID: 38349538
[TBL] [Abstract][Full Text] [Related]
2. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
[TBL] [Abstract][Full Text] [Related]
3. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
[TBL] [Abstract][Full Text] [Related]
4. The impact of facility characteristics on Merkel cell carcinoma outcomes: A retrospective cohort study.
Cheraghlou S; Agogo GO; Girardi M
J Am Acad Dermatol; 2023 Jul; 89(1):70-80. PubMed ID: 31473294
[TBL] [Abstract][Full Text] [Related]
5. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study.
Bhatia S; Nghiem P; Veeranki SP; Vanegas A; Lachance K; Tachiki L; Chiu K; Boller E; Bharmal M
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981787
[TBL] [Abstract][Full Text] [Related]
6. Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.
Bhanegaonkar A; Liu FX; Boyd M; Fulcher N; Kim R; Krulewicz S; Smith J; Cowey CL
Oncologist; 2021 Sep; 26(9):e1633-e1643. PubMed ID: 34101298
[TBL] [Abstract][Full Text] [Related]
7. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
8. First-line Immunotherapy for Metastatic Merkel Cell Carcinoma: Analysis of Real-world Survival Data and Practice Patterns.
Kakish H; Sun J; Ammori JB; Hoehn RS; Rothermel LD
Am J Clin Oncol; 2024 Apr; ():. PubMed ID: 38587336
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Gaiser MR; Bongiorno M; Brownell I
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
[TBL] [Abstract][Full Text] [Related]
10. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
12. Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma.
Nguyen AT; Luu M; Lu DJ; Hamid O; Mallen-St Clair J; Faries MB; Gharavi NM; Ho AS; Zumsteg ZS
J Am Acad Dermatol; 2021 Feb; 84(2):312-320. PubMed ID: 31954753
[TBL] [Abstract][Full Text] [Related]
13. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck.
Jacobs D; Olino K; Park HS; Clune J; Cheraghlou S; Girardi M; Burtness B; Kluger H; Judson BL
Otolaryngol Head Neck Surg; 2021 Jun; 164(6):1214-1221. PubMed ID: 33079010
[TBL] [Abstract][Full Text] [Related]
14. Merkel Cell Carcinoma of Unknown Primary Origin.
Francetić H; Simetić L; Tomasović Lončarić Č; Štulhofer Buzina D; Čeović R
Acta Dermatovenerol Croat; 2023 Dec; 31(3):153-155. PubMed ID: 38439727
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.
D'Angelo SP; Russell J; Lebbé C; Chmielowski B; Gambichler T; Grob JJ; Kiecker F; Rabinowits G; Terheyden P; Zwiener I; Bajars M; Hennessy M; Kaufman HL
JAMA Oncol; 2018 Sep; 4(9):e180077. PubMed ID: 29566106
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base.
Bhatia S; Storer BE; Iyer JG; Moshiri A; Parvathaneni U; Byrd D; Sober AJ; Sondak VK; Gershenwald JE; Nghiem P
J Natl Cancer Inst; 2016 Sep; 108(9):. PubMed ID: 27245173
[TBL] [Abstract][Full Text] [Related]
17. Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel.
Averbuch I; Stoff R; Miodovnik M; Fennig S; Bar-Sela G; Yakobson A; Daliot J; Asher N; Fenig E
Cancer Med; 2023 Jun; 12(11):12065-12070. PubMed ID: 37012213
[TBL] [Abstract][Full Text] [Related]
18. Overall Survival After Mohs Surgery for Early-Stage Merkel Cell Carcinoma.
Cheraghlou S; Doudican NA; Criscito MC; Stevenson ML; Carucci JA
JAMA Dermatol; 2023 Oct; 159(10):1068-1075. PubMed ID: 37610773
[TBL] [Abstract][Full Text] [Related]
19. Survival Benefit of Guideline-Concordant Postoperative Radiation for Local Merkel Cell Carcinoma.
Wong WG; Stahl K; Olecki EJ; Holguin RP; Pameijer C; Shen C
J Surg Res; 2021 Oct; 266():168-179. PubMed ID: 34015514
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Lymph Node Ratio Association With Long-term Patient Survival After Surgery for Node-Positive Merkel Cell Carcinoma.
Cheraghlou S; Agogo GO; Girardi M
JAMA Dermatol; 2019 Jul; 155(7):803-811. PubMed ID: 30825411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
